Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Thirty-two patients with squamous cell carcinomas of the head and neck and three patients with parotid gland carcinomas were treated with methotrexate 40 mg/m2 followed 1 h later by 5-fluorouracil 600 mg/m2. Treatments were repeated on day 8, then every 2 weeks, toxicity permitting. Of 30 evaluable patients with squamous cell carcinomas, 9 (30%) achieved a partial (8) or complete (1) remission. Performance status and prior treatment history appeared to affect the probability of response. The original site of the primary had no apparent effect on response rate. Six patients having objective tumor regression but less than the amount required for classification as partial remission all had marked symptomatic relief and had "response" durations and survivals quite comparable to those in patients achieving partial remission. One patient with a parotid gland carcinoma attained a complete remission, one had a minor response, and one refused to return for follow-up. Myelosuppression and stomatitis were dose-limiting in some patients, although the regimen was generally well tolerated. Three patients (9%) developed cerebellar toxicity, suggesting that prior ethanol abuse could possibly predispose to this side effect.
Stewart
D J
DJ
Maroun
J A
JA
Cripps
C
C
Young
V
V
Laframboise
G
G
Gerin-Lajoie
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011379:Prognosis
D005472:Fluorouracil; D008727:Methotrexate